Kaposi sarcoma - null regimens
The purpose of this page is to provide references to "null therapy" such as placebo and observation. These references provide further insight into the historical development of the treatment landscape. See the main KS page for regimens that include active anticancer treatment.
All lines of therapy
|Study||Dates of enrollment||Evidence||Comparator||Comparative Efficacy|
|Walmsley et al. 1999||1996-04 to 1997-07||Phase 3 (C)||Alitretinoin||Inferior ORR|
|Bodsworth et al. 2001||NR||Phase 3 (C)||Alitretinoin||Inferior ORR|
|Noy et al. 2005 (AMC 013)||1998-2001||Phase 3 (C)||IM-862||Seems to have superior TTP|
No active antineoplastic treatment.
- Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B; Panretin Gel North American Study Group. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. J Acquir Immune Defic Syndr. 1999 Nov 1;22(3):235-46. link to original article PubMed
- Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R; International Panretin Gel KS Study Group. Phase III vehicle-controlled, multi-centered study of topical alitretinoin gel in cutaneous AIDS-related Kaposi's sarcoma. Am J Clin Dermatol. 2001;2(2):77-87. link to original article PubMed
- AMC 013: Noy A, Scadden DT, Lee J, Dezube BJ, Aboulafia D, Tulpule A, Walmsley S, Gill P; AIDS Malignancy Consortium. Angiogenesis inhibitor IM862 is ineffective against AIDS-Kaposi's sarcoma in a phase III trial, but demonstrates sustained, potent effect of highly active antiretroviral therapy: from the AIDS Malignancy Consortium and IM862 Study Team. J Clin Oncol. 2005 Feb 10;23(5):990-8. Epub 2004 Dec 14. link to original article PubMed